Detection Of EGFR Mutation In NSCLC And Paired Plasma

[Objective]:To investigate the mutation of epidermal growth factor receptor(EGFR)in patients with non-small cell lung cancer inUniversity Yunnan Cancer Hospital(Third Affiliated Hospital of Kunming Medical).[METHODS]:EGFR mutation was detected by the use of Amplification Refractory Mutation System(ARMS)polymerase chain reaction(PCR)using DNA samples from 54 pathologically confirmed NSCLC tissue specimens and corresponding plasma samples from the same patients.The relationship between EGFR mutations,clinical factors,sample type(tissue and plasma)and histologic type(adenocarcinoma)were further explored.[RESULT]:1.We found the mutation rate was 44.4%in tissue samples and 22.2%for plasma samples.We found female(P= 0.01),non-smoker(p = 0.005),and tissue specimen(p = 0.001)and advance tumor stage(P=0.003)were associated with higher EGFR mutation rate.2.There was no significant difference in the rate of mutation between adenocarcinoma and squamous cell carcinoma.3.The most common mutations were exon 19 deletions(37.5%)and L858R point(37.5%)mutation.The sensitivity of plasma was 45.8%,the specificity was 96.7%,the positive predictive value(PPV)was 91.7%,and the negative predictive value(NPV)was 69.04%.[CONCLUSION]:.The mutation rate of EGFR in women,non-smoker,tumor progression and adenocarcinoma is higher than in smoker,early tumor stage and squamous cell carcinoma.2.The detection of cfDNA EGFR mutation in plasma samples is a moderately sensitive and specific method.